Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Scandal In Waiting?

Executive Summary

Headlines about potential carcinogens in the drug supply have been a chronic, low-level challenge for the US FDA’s reputation in recent years. A recent Congressional hearing shows how much tinder is now laid for a potential flare up into a full-on crisis in confidence in the agency.

You may also be interested in...



Quality Lowdown: FDA Defends Nitrosamine Testing Methods While US, EU Enforcement Continues

The crisis of nitrosamine contamination in prescription drug products continues to roil the world’s health authorities and prompts debate on the different approaches used to measure these impurities. Meanwhile, an Austrian firm gets inspected despite the pandemic and yet another homeopathic firm gets an FDA warning letter.

US FDA And Congress: Criticism Of Leadership Ramping Up, But Bipartisan Truce Holds For Now

Senate Finance Committee’s hearing on FDA’s overseas inspection program suggests that agency’s status as a rare focus for bipartisan support amid the Trump Presidency is getting more tenuous – but still holding for the time being.

US FDA And Congress: Criticism Of Leadership Ramping Up, But Bipartisan Truce Holds For Now

Senate Finance Committee’s hearing on FDA’s overseas inspection program suggests that agency’s status as a rare focus for bipartisan support amid the Trump Presidency is getting more tenuous – but still holding for the time being.

Related Content

Topics

UsernamePublicRestriction

Register

PS142346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel